Search results
Found 16123 matches for
Healthy Minds from 0-100 years: Optimising the use of European brain imaging cohorts
As part of EU Horizon 2020, we integrate 11 longitudinal mostly population-based cohort studies investigating cognitive and mental health across the life-span (n=18 500). Many subjects (n=6000) underwent MRI examinations (40 000 exams) in addition to clinical cognitive and mental health data and genetic sampling. We plan to link those databases to national databases (registries), biobanks and data from other large studies
Oxfordshire Education Authority Communication and Interaction (C&I) Team
Provide support for children with an ASD diagnosis in schools.
Autism Family Support Oxfordshire
Autism Family Support Oxfordshire use understanding, expertise, and a lot of fun and care to support the development and wellbeing of children and young adults on the autism spectrum, and their families.
Neuroimaging of Reward Group (NRG)
Clinical collaborators wanted*
Seminar Series - Thursday 13th March 2014
The most recent seminar 'Sleep and Autism' took place in the Department of Psychiatry at the Warneford site.
Professor Charles Newton
I am conducting research on genetics of autism, epilepsy and psychosis in sub-Saharan Africa. My research in Oxford focuses on autism and neurodevelopmental disorders, particular the causes and consequences of these conditions in Europe.
20th Annual Meeting Cognitive Neuroscience Society
Took place in San Francisco in April 2013
Traumatic brain injury (TBI) as a substantial cause of disability (Seena Fazel)
Traumatic brain injury (TBI) is a substantial cause of disability with high societal costs worldwide. In the US, where surveillance started in 1989, 3.2 million persons or 1% of the population have sustained a TBI in their lifetime. Similarly large numbers have been reported in European countries. The public health burden may increase in the next few decades, as road traffic accidents, a leading cause of TBI and currently the ninth largest contributor to disability-adjusted living years globally, are estimated to become the third largest contributor by 2030 with a particularly large rise in middle income countries. One high risk group are prisoners, where high rates of TBI have been reported, including in juvenile prisons, and where little is known about this TBI contributes to adverse outcomes following release.
The influence of stress and genotype on the response to a dopaminergic drug (Paul Harrison & Liz Tunbridge)
Tolcapone is an inhibitor of the dopamine-metabolizing enzyme catechol-o-methyltransferase (COMT), used in the adjunctive treatment of Parkinson’s disease. Our recent study (Farrell SM et al, Biological Psychiatry 2012; 71: 538-544), and others, show that it also has effects in healthy subjects on cognition and risk taking.